Pharmabiz5h
PeproMene Bio receives $11 million investment from IFLI to advance BAFF-R CAR T-cell therapy for relapsed/refractory follicular lymphoma
Irvine, California Monday, December 23, 2024, 18:00 Hrs [IST] ...
Pharmabiz7h
US FDA approves Mesoblast’s mesenchymal stromal cell therapy, Ryoncil for steroid-refractory aGvHD in children 2 months and older
US FDA approves Mesoblast’s mesenchymal stromal cell therapy, Ryoncil for steroid-refractory aGvHD in children 2 months and older: Melbourne, Australia Monday, December 23, 2024 ...
Pharmabiz6h
Bhaskar Tare, director of Gloocal Communications, felicitated with Pride of Spandan Award 2024 for contribution in healthcare
Bhaskar Tare, director of Gloocal Communications, felicitated with Pride of Spandan Award 2024 for contribution in healthcare: Our Bureau, Mumbai Monday, December 23, 2024, 17:15 ...
Pharmabiz6h
StemCyte announces positive results from phase IIa trial of HPC, cord blood for treating post-Covid syndrome
StemCyte announces positive results from phase IIa trial of HPC, cord blood for treating post-Covid syndrome: Baldwin Park, California Monday, December 23, 2024, 17:00 Hrs [IST] S ...
Pharmabiz13h
Pfizer’s BRAFTOVI combination regimen receives US FDA approval for treatment of metastatic colorectal cancer
Pfizer’s BRAFTOVI combination regimen receives US FDA approval for treatment of metastatic colorectal cancer: New York Monday, December 23, 2024, 10:00 Hrs [IST] Pfizer Inc anno ...
Pharmabiz8h
US FDA approves Ionis Pharma’s Tryngolza to treat adults living with familial chylomicronemia syndrome as an adjunct to diet
US FDA approves Ionis Pharma’s Tryngolza to treat adults living with familial chylomicronemia syndrome as an adjunct to diet: Carlsbad, California Monday, December 23, 2024, 15: ...
Pharmabiz9h
GangaGen secures additional US$ 7.9 million from CARB-X for pre-clinical development multidrug-resistant Klebsiella pneumoniae
GangaGen secures additional US$ 7.9 million from CARB-X for pre-clinical development multidrug-resistant Klebsiella pneumoniae: Our Bureau, Bengaluru Monday, December 23, 2024, 14 ...
Pharmabiz6h
Zealand Pharma’s NDA for glepaglutide gets US FDA complete response letter for treatment of short bowel syndrome
Zealand Pharma A/S, a biotechnology company focused on the discovery and development of innovative peptide-based medicines, announced that the US Food and Drug Administration (FDA) has issued a ...
Pharmabiz10h
Vittoria Biotherapeutics doses first patient in phase 1 clinical trial of VIPER-101
Vittoria Biotherapeutics doses first patient in phase 1 clinical trial of VIPER-101: Philadelphia Monday, December 23, 2024, 13:00 Hrs [IST] Vittoria Biotherapeutics, Inc, a clini ...
Pharmabiz12h
Myriad Genetics’ RiskScore named one of the top 10 significant advances in genomic medicine
Myriad Genetics’ RiskScore named one of the top 10 significant advances in genomic medicine: Salt Lake City Monday, December 23, 2024, 11:00 Hrs [IST] Myriad Genetics, Inc, a le ...
Pharmabiz14h
Valneva signs exclusive license agreement with Serum Institute of India for its single-shot chikungunya vaccine to supply in Asia
Saint-Herblain, France Monday, December 23, 2024, 09:00 Hrs [IST] ...
Pharmabiz12h
Session on diagnosis and treatment illuminates latest advances in migraine diagnosis and treatment
Session on diagnosis and treatment illuminates latest advances in migraine diagnosis and treatment: Our Bureau, Mumbai Monday, December 23, 2024, 11:30 Hrs [IST] In a landmark eve ...